Interim Report January - June 2008 Tripep AB (publ)

 Research and development costs amounted to SEK 11.8 (7.7) million
 The loss after tax was SEK -18.1 (-13.8) million
 Earnings per share were SEK -2.57 (-2.54)
 The company had no net sales for the period
 A reverse stock split 1:10 has been carried out
 The company intends to carry out a rights issue during third quarter 2008. Some of the major suppliers have agreed to postpone their invoicing pending the capital injection from the upcoming rights issue
 The ChronVac-C®study shows positive efficacy data i.e activation of immune responses and lowering of viral levels in the blood in hepatitis C patients
 The first nine patients in the ChronVac-C®study either have concluded or are in treatment without any serious side effects
 Patent application filed for a new antibiotic-free formulation of ChronSeal® in collaboration with Kringle Pharma, Inc.
 New application filed with the Swedish Medical Products Agency for a phase II trial on ChronSeal®
 Tripep secured a first US patent on a new type of immunotherapy against HIV-1